Heather Llewellyn, PhD
Prometheus Biosciences, Inc.
Heather Llewellyn is currently a Principal Scientist in Immunology Discovery at Prometheus Biosciences, a wholly owned subsidiary of Merck & Co, Inc. As a trained immunologist, she is biology lead in discovery and manages collaborations for translational research across I&I.
Heather earned her PhD in Experimental Pathology at the University of Virginia in Charlottesville, VA, studying the molecular mechanisms of B cell mediated responses in atherosclerosis. She continued her immunology training at UVA as a postdoc to understand the molecular and cellular mechanisms of the kidney microenvironment that controlled the switch from acute kidney injury to chronic kidney disease and fibrosis. In her transition to industry, she joined the Immunotoxicology group in Drug Safety R&D at Pfizer as a postdoc to characterize a mouse model of immune checkpoint inhibitor induced liver toxicity. In her current role, Heather is the biology lead for TL1A and drives academic and CRO partnership strategy for translational programs including precision medicine.